Zai Lab Limited (ZLAB)

NGM – Real vaqt narxi. Valyuta: USD

25.47

-0.53 (-2.04%)

Bozor ochiq: Aug 12, 2026, 1:31 PM EDT

26.00

0.00 (0.00%)

Oldingi bozordan keyin: Aug 11, 2026, 7:34 PM EDT

07.08.2026

Zai Lab Q2 Earnings Call Highlights

Zai Lab NASDAQ: ZLAB said its second-quarter net product revenue rose 11% sequentially to $105.8 million as the company continued to invest in a pipeline it expects to support a transition into a global biopharmaceutical business.

06.08.2026

Zai Lab Limited (ZLAB) Q2 2026 Earnings Call Transcript

06.08.2026

Here's What Key Metrics Tell Us About Zai Lab Limited (ZLAB) Q2 Earnings

The headline numbers for Zai Lab Limited (ZLAB) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

06.08.2026

Zai Lab Announces Second Quarter 2026 Financial Results and Recent Corporate Updates

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced financial results for the second quarter of 2026, along with recent product highlights and corporate updates. “Zai Lab is entering an exciting new chapter in our evolution,” said Dr. Samantha Du, Founder, Chairperson and Chief Executive Officer of Zai Lab. “Over the past several years, we have evolved from bringing innovative medicines to patients in China to becoming a global biopharmaceuti.

03.08.2026

U.S. FDA Grants Orphan Drug Designation to Zai Lab's DLL3-Targeting ADC Zocilurtatug Pelitecan (Zoci) for the Treatment of Neuroendocrine Carcinomas (NECs)

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to zocilurtatug pelitecan (zoci, formerly ZL-1310), the Company's potential first-in-class Delta-like ligand 3 (DLL3) antibody-drug conjugate (ADC), for the treatment of neuroendocrine carcinomas (NECs). NECs are aggressive malignancies that frequently express DLL3. There are no available targeted therapies.

Zai Lab Limited (ZLAB)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Zai Lab Limited (ZLAB)

Zai Lab Q2 Earnings Call Highlights

Zai Lab Limited (ZLAB) Q2 2026 Earnings Call Transcript

Here's What Key Metrics Tell Us About Zai Lab Limited (ZLAB) Q2 Earnings

Zai Lab Announces Second Quarter 2026 Financial Results and Recent Corporate Updates

U.S. FDA Grants Orphan Drug Designation to Zai Lab's DLL3-Targeting ADC Zocilurtatug Pelitecan (Zoci) for the Treatment of Neuroendocrine Carcinomas (NECs)

Zai Lab Q2 Earnings Call Highlights

Zai Lab Limited (ZLAB) Q2 2026 Earnings Call Transcript

Here's What Key Metrics Tell Us About Zai Lab Limited (ZLAB) Q2 Earnings

Zai Lab Announces Second Quarter 2026 Financial Results and Recent Corporate Updates

U.S. FDA Grants Orphan Drug Designation to Zai Lab's DLL3-Targeting ADC Zocilurtatug Pelitecan (Zoci) for the Treatment of Neuroendocrine Carcinomas (NECs)

Videolar

No Data

Press-relizlar

Zai Lab Announces Second Quarter 2026 Financial Results and Recent Corporate Updates

U.S. FDA Grants Orphan Drug Designation to Zai Lab's DLL3-Targeting ADC Zocilurtatug Pelitecan (Zoci) for the Treatment of Neuroendocrine Carcinomas (NECs)

Search stocks

Zai Lab Limited (ZLAB)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Zai Lab Limited (ZLAB)

Zai Lab Q2 Earnings Call Highlights

Zai Lab Limited (ZLAB) Q2 2026 Earnings Call Transcript

Here's What Key Metrics Tell Us About Zai Lab Limited (ZLAB) Q2 Earnings

Zai Lab Announces Second Quarter 2026 Financial Results and Recent Corporate Updates

U.S. FDA Grants Orphan Drug Designation to Zai Lab's DLL3-Targeting ADC Zocilurtatug Pelitecan (Zoci) for the Treatment of Neuroendocrine Carcinomas (NECs)

Zai Lab Q2 Earnings Call Highlights

Zai Lab Limited (ZLAB) Q2 2026 Earnings Call Transcript

Here's What Key Metrics Tell Us About Zai Lab Limited (ZLAB) Q2 Earnings

Zai Lab Announces Second Quarter 2026 Financial Results and Recent Corporate Updates

U.S. FDA Grants Orphan Drug Designation to Zai Lab's DLL3-Targeting ADC Zocilurtatug Pelitecan (Zoci) for the Treatment of Neuroendocrine Carcinomas (NECs)

Videolar

No Data

Press-relizlar

Zai Lab Announces Second Quarter 2026 Financial Results and Recent Corporate Updates

U.S. FDA Grants Orphan Drug Designation to Zai Lab's DLL3-Targeting ADC Zocilurtatug Pelitecan (Zoci) for the Treatment of Neuroendocrine Carcinomas (NECs)